Health TrialsbyHealthPanel

Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

1

Review clinical trials related to Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

This single-arm phase II trial enrolls patients with RAS-mutant, microsatellite-stable (MSS) unresectable colorectal cancer liver metastases receiving first-line treatment with Retlirafusp alfa combined with XELOX (capecitabine plus oxaliplatin) and bevacizumab. The primary endpoint is objective response rate (ORR). A total of 46 patients will be enrolled, and the study is expected to be completed between 2026 and 2029.

Participants needed: 46
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Dai, GuanghaiUpdated: Sep 1, 2026Locations: 1
Eligibility criteria

Age: 18-75 years; [+9]

History of or concurrent other malignant tumors, excluding cured basal cell carc... [+13]

Read more